Table 2. Cox regression of overall survival in entire AML cohort.
| Covariates | HR | 95% CI | p-Value |
|---|---|---|---|
| Age | 1.03 | 1.01 – 1.05 | 0.001 |
| Risk group | |||
| • *Intermediate riska | 1.76 | 0.92 – 3.37 | 0.038 |
| • *High riska | 3.23 | 1.51 – 6.91 | 0.002 |
| TERT rs2853669 C/Tb | 1.35 | 0.87 – 2.10 | 0.110 |
| TERT rs2853669 C/Cb | 1.74 | 1.03 – 2.94 | 0.024 |
| Treatmentc | 0.5 | 0.29 – 0.84 | 0.002 |
a
Compared to low risk,
b
Compared to T/T
c
Chemo + allo-SCT compared to chemo only
*Intermediate risk: FLT3-ITD positive/NPM1 mutation positive or FLT3-ITD negative/NPM1 mutation negative or FLT3-ITD negative/monoallelic and or CEBPA wild type patients, *High risk: FLT3-ITD positive/NPM1 mutation negative NK-AML patients, *Low risk: FLT3-ITD negative/NPM1 mutation positive or FLT3-ITD negative/biallelic CEBPA mutation patients.